Biogen shares drop over 8% after mixed Alzheimer's trial data and FDA move

Traders Union
All News
Financial News
Biogen slides 8.21% today

Highlights

Biogen's investigational Alzheimer's therapy, diranersen, showed significant slowing of cognitive decline in Phase 2, prompting a move to Phase 3 trials.
FDA approved a new at-home subcutaneous starting dose for Leqembi, improving accessibility for Alzheimer's patients and potentially expanding the treatment market.
Despite strong news, Biogen trades near $191.87 under selling pressure, with technical signals mixed and expected to consolidate between $177.68 and $199.68 over the next week.

Trading spikes as positive Alzheimer’s updates meet persistent selling

Biogen reported Phase 2 CELIA trial results for diranersen, a tau-targeting investigational therapy for early Alzheimer's disease, showing significant slowing of cognitive decline and biomarker reductions in treated patients compared to placebo. Plans were announced to advance diranersen into Phase 3 testing. Separately, the U.S. FDA approved a new subcutaneous, at-home starting dose for Leqembi, an Alzheimer's medication co-developed by Biogen and Eisai, potentially broadening patient accessibility. These updates were accompanied by increased trading activity, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, adopts a cautious view in light of Biogen’s sharp drop. He sees the stock’s inability to reclaim key moving averages as a clear sign of ongoing seller dominance. Even with positive news from the Alzheimer’s programs, technical and sentiment signals fail to confirm a reversal. The downside gap and persistent near-term weakness suggest institutional confidence is shaky. Kharitonov stresses the relevance of overbought momentum signals, pointing to risk of further selling. "For now, any upward move in Biogen looks fragile — aggressive buyers should stay defensive until the volatility recedes."

Viktoras Karapetjanc, expert at Traders Union, believes Biogen’s structure remains bullish despite recent volatility. He notes the progress in Alzheimer’s programs and regulatory approvals as strong fundamental catalysts. Karapetjanc sees the FDA’s decision on Leqembi as an important milestone for patient access and future revenue streams. The current correction offers opportunities for longer-term investors, particularly with consolidation expected. "With new clinical achievements and macro tailwinds, I expect Biogen to resume upward momentum and target resistance at $195.25 in the coming days."

Parshwa Turakhiya, analyst, sees short-term volatility dominating sentiment in Biogen after the recent price gap and spike in trading volume. He notes conflicting momentum signals, with intraday buyers facing exhaustion while broader indicators hint at an oversold setup. Turakhiya points to sideways action as the likely near-term scenario, with quick rebounds possible if support at $189.43 holds. "This is a prime setup for active traders — nimble entries near support may capture rapid reversals as sentiment resets."

Seller momentum dominates as short-term averages break and signals diverge

Biogen is trading below its 20-day and 50-day moving averages ($204.21 and $197.78, respectively) but remains above the 200-day moving average at $179.46. This setup suggests sellers are pressuring the stock in the short and medium term, even as the long-term trend holds a bullish alignment. The nearest resistance is at $195.25 and immediate support is at $189.43. Momentum signals show the MACD indicates strong buying pressure; however, the Average Directional Index (ADX) gives a neutral reading, pointing to a lack of trend strength. The Relative Strength Index (RSI) and Stochastic RSI both show buy signals, suggesting no immediate overbought risk, whereas the Commodity Channel Index (CCI) is neutral. Bull/Bear Power (BBP) is positive at 5.6, confirming buyers dominate intraday momentum, but it also flags an overbought signal. Biogen has dropped to $191.87, down $17.16 or 8.21% with a pronounced downside gap of about $8.69 (4.16%). Price is holding near the day’s low, and intraday volatility stands at 5.95%, reflecting sustained pressure after the open. Momentum indicators broadly match the day’s weakness, but the BBP’s overbought tag signals possible exhaustion as buyers lose dominance.

Earlier, analysts noted that Biogen shares faced persistent downside pressure as technical momentum remained weak despite positive clinical and regulatory milestones. With recent indicators reflecting mixed momentum and elevated volatility, traders should monitor for a potential breakout above $195.25 or a breakdown below $189.43 as signals for the next directional move.

Source of Data: BIIB Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.